Takeda's seizure drug fails to meet main goal in late-stage studies

[June 17, 2024]  (Reuters) - Japan's Takeda said on Monday its experimental drug to treat epileptic disorders failed to meet the main goal in two late-stage studies.

The drug, soticlestat, was being tested in adult and pediatric patients with Dravet syndrome and Lennox-Gastaut syndrome.

These are severe forms of epilepsy characterized by frequent, prolonged seizures, that typically becomes apparent during infancy or early childhood.

Takeda plans to discuss with regulatory authorities to determine next steps.

(Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)

Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018. REUTERS/Kim Kyung-Hoon/File Photo

[© 2024 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.